Last Price
0.038
Today's Change
-0.001 (2.56%)
Day's Change
0.038 - 0.039
Trading Volume
11,101,427
Market Cap
282 Million
Shares Outstanding
7 Billion
Avg Volume
23,554,692
Avg Price (50 Days)
0.05
Avg Price (200 Days)
0.07
PE Ratio
-1.90
EPS
-0.02
Earnings Announcement
26-Feb-2025
Previous Close
0.04
Open
0.04
Day's Range
0.038 - 0.039
Year Range
0.035 - 0.13
Trading Volume
11,101,427
1 Day Change
-2.56%
5 Day Change
-7.32%
1 Month Change
-22.45%
3 Month Change
-26.92%
6 Month Change
-45.71%
Ytd Change
-65.45%
1 Year Change
-58.24%
3 Year Change
-92.83%
5 Year Change
-26.92%
10 Year Change
283.45%
Max Change
-99.74%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.